RhythmX AI

The company is AI native by construction rather than by repositioning. Generative and predictive models are the product, producing the recommendations that constitute the entire value proposition, and there is no prior system of record or services business underneath. It draws on the technical depth of its parent group, which the company describes as 250 data scientists and a thousand people dedicated to healthcare. Note for the future rather than for this grade: the merger with a patient engagement company broadens the combined entity considerably, and a later assessment should check whether the AI remains the centre or becomes one component of a wider platform.

This product recommends clinical actions rather than reporting clinical facts, and that raises the bar it has to clear. Its stated outputs include recommended laboratory tests, imaging, medications and follow ups, plus routing a patient to a particular clinician type or channel. This index has consistently graded order adjacent recommendation at C where nothing is published about how the recommendations behave, on the reasoning that an error in a note is a documentation problem while an error in a recommended order is a clinical action. No confidence threshold, no routing rule, no abstention behaviour for a thin record and no error rate was located, and no statement describes what a clinician must verify before acting. The drill down capability is a genuine mitigation and is the reason this is not lower, since a physician can interrogate the basis of a recommendation rather than accept it blind.

The platform is described as combining predictive algorithms with generative capability over longitudinal data, and clinicians can drill into a recommendation to see what sits behind it, which is a real verification affordance rather than a black box. Beyond that nothing is disclosed: no model or model family is named, no accuracy figure exists for any recommendation type, no validation methodology is published, and no model card was located. For a product that recommends laboratory tests, imaging and medications, per recommendation type performance is the disclosure that matters and none of it exists publicly.

One named deployment carrying real weight, and one number that needs reading carefully. Presbyterian Healthcare Services expanded to 200 primary care clinicians in February 2026, described as a first full system deployment rather than a pilot, with the system's chief medical information officer named and quoted. The reported early result carries a genuine denominator, which is more than most vendors offer: more than 200 combined HCC and non HCC conditions identified across more than 10,000 patient encounters within weeks of launch. That works out at roughly two percent of encounters, a modest and therefore plausible figure rather than an inflated one, though the vendor does not present it that way. Held at B because it is a single site, vendor published, with no independent evaluation, and because conditions identified is a volume measure rather than a measure of whether the identifications were correct or acted upon. A clinical advisory board with named executives from Prime Healthcare, Sentara Health and Mass General Brigham adds credibility to the design process without being evidence about outcomes.

No retention period, no statement on whether customer data is used to train or improve models, and no de identification posture was located. Not Rated records absent evidence rather than an assessed weakness. The scope makes the questions material and unusually broad: the platform unites more than ten data sources including EHR content, payer and financial data, and social and lifestyle data, so the estate assembled per patient reaches well beyond the clinical record. The merger with a patient engagement company adds a further question about what flows between the two sides.

No HIPAA compliance statement and no business associate agreement terms were located on any retrieved surface. A BAA plainly exists given a full system deployment at a nine hospital organisation, but the index grades what is disclosed. Establish the contracting entity following the Get Well merger, since the counterparty may now differ from the one originally engaged.

No SOC 2, HITRUST, ISO 27001 or other attestation was located, and no trust centre or security page was found. Not Rated reflects absent retrieval rather than an assessed weakness. Worth requesting early given the breadth of data assembled per patient.

No FDA clearance, device authorisation or clinical decision support exemption analysis was located. Not Rated reflects absent retrieval, and of every record built in this lane this is the one where the question is most live. The product generates patient specific recommendations for laboratory tests, imaging and medications, which is squarely the territory the software as a medical device analysis addresses. Grounding in named clinical policies and published guidelines may support an exemption position, which is the same reasoning this index raised for Avo, but that analysis should be documented by the vendor rather than assumed by the buyer. Ask to see it.

The grade describes disclosure and incentive structure, and the counterweights belong alongside. Recommendations are traceable through a drill down interface, the clinical advisory board carries named senior clinicians from three major systems, and the deploying organisation's own chief medical information officer framed the adoption in terms of responsible AI use rather than novelty, which is a stance worth crediting. Against that, the headline measured outcome at the named deployment is the identification of HCC and non HCC conditions, and the stated purpose includes strengthening performance in value based arrangements, which places the product on the risk adjustment gradient this index tracks across the category. Separately, no fairness, subgroup or demographic performance disclosure was located, and that gap is consequential here in a way it is not everywhere: the platform explicitly incorporates social determinants and lifestyle data into recommendations, and a model that uses social data to shape clinical recommendations is precisely the kind that requires subgroup performance reporting rather than the kind that can defer it.

The company describes the platform as EHR agnostic and, more usefully, its named deployment demonstrates it: clinicians at Presbyterian Healthcare Services work with the data presented in a single consolidated workflow inside their Epic EHR. Ingestion spans more than ten source types including EHR data, clinical policies and guidelines, payer and financial data and social data, which is genuine breadth rather than a single feed. Held at B because Epic is the only EHR evidenced, no other system is named, no integration standard or mechanism is described, and no marketplace listing or third party technical review was located to corroborate the agnostic claim.

No hosting model, cloud provider, region, residency commitment or customer hosted option was located, and nothing describes where the assembled multi source patient record is processed or held. Not Rated reflects absent retrieval.

No price, tier or pricing mechanism was located on any retrieved surface. Not Rated is the house convention for absent pricing rather than a low grade. The Get Well merger adds a question worth asking during evaluation: whether the precision care platform can still be licensed independently of the patient engagement product, or whether the combined entity now sells them together.

Deliberately focused rather than broad, and the focus is a strength. The platform targets primary care and whole person management of chronic conditions, which the company identifies as the setting where fragmented data and time pressure bite hardest, and the named deployment is a primary care clinician population. Coverage extends across clinical, laboratory, social determinant and lifestyle dimensions within that setting, and routing logic reaches beyond the primary care physician to advanced practice providers and specialists. Graded B rather than A because the depth is within one care setting, the range of chronic and acute conditions covered is described as expanding rather than complete, and no specialty specific instrument level behaviour was located.